Chinese COVID-19 vaccine developer Clover Biopharmaceuticals said on Thursday it raised $240 million in net proceeds in an initial public offering (IPO) of shares in Hong Kong. BEIJING, Nov 5 (Reuters ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results